Market News & Trends
Catalent Pharma Solutions & NewMarket Sign Development Agreement
Catalent Pharma Solutions and NewMarket Pharmaceuticals LLC recently announced they have entered into an agreement to jointly formulate and develop a portfolio of products for…
Curis & Debiopharm Announce Initiation of Phase Ib Expansion Study
Curis, Inc. and Debiopharm Group recently announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90)…
DARA BioSciences Signs Exclusive Agreement With Uman Pharma
DARA BioSciences, Inc. recently announced it entered into an exclusive US agreement with Uman Pharma Inc. for commercial rights to gemcitabine, DARA's second newly licensed…
IntelGenx Announces License Agreement With Edgemont Pharmaceuticals
IntelGenx Corp. recently announced it has entered into an exclusive agreement with Edgemont Pharmaceuticals, LLC for the commercialization of IntelGenx's lead product CPI-300 in US.…
Malvern & Postnova to Deliver Solution for Characterizing Challenging Particulate Systems
Malvern Instruments and Postnova Analytics recently announced they are co-operating to deliver the combined FFF (Field-Flow Fractionation) and DLS (Dynamic Light Scattering) solutions that today…
Sandoz Buys Rights to Apricus Biosciences' Drug for $28 Million
Apricus Biosciences, Inc. recently announced its wholly owned subsidiary NexMed, Inc. has signed with Sandoz, a division of Novartis, an exclusive collaboration for Germany to…
Vectron Biosolutions Obtains Strong Results for Biosimilar Production
Vectron Biosolutions recently announced they have obtained strong results for manufacture of selected biosimilar proteins using its proprietary E. coli expression technology. The study was…
Watson Seeks Brand-Drug Profits in Shift From Copycats
Watson Pharmaceuticals Inc. CEO Paul Bisaro is looking to acquire brand-name drug assets and make a future ""˜transformational" purchase as he reshapes the generic-drug maker.…
2/14/2012
Bend Research Signs License Agreement With Eli Lilly & Company Bend Research Inc., a leading independent drug formulation development and manufacturing company, recently announced it…
Bend Research Signs License Agreement With Eli Lilly & Company
Bend Research Inc., a leading independent drug formulation development and manufacturing company, recently announced it has entered into a licensing agreement with Eli Lilly and…
CHEMO & Particle Sciences Partner to Provide the Only Development-to-Commercialization Solution
Particle Sciences Inc. and CHEMO recently announced they have formed a partnership to offer complete contract product development and commercial manufacturing of hormone-eluting devices. Particle Sciences…
Cytomedix Acquires Aldagen
Cytomedix, Aldagen, acquisition details, 5 million dollar stock purchase, PRP platform technology, Martin Rosendale, cell selection technology Cytomedix, Inc. recently announced the completion of the…
Daiichi Sankyo Seeks to Acquire Three Indian Pharma Firms
Daiichi Sankyo, which in 2008 acquired Ranbaxy, is in takeover talks with at least three mid-sized Indian pharmaceutical companies. Daiichi Sankyo has appointed IMS Consulting…
2/7/2012
Foster Analytical Services Speed Time to Market for Drug Delivery Formulations Foster Delivery Science, a business unit for Foster Corporation, recently announced it has added…
Alize Pharma Licenses ASPAREC Therapy for ALL to EUSA Pharma
Alize Pharma II, recently announced the signing of a licensing agreement with EUSA Pharma for ASPAREC, a new L-asparaginase product currently in Phase I clinical…
Celerion First Early-Stage CRO to Adopt Participant Verification System
Celerion recently announced it has implemented VCT Verify from Verified Clinical Trials, to instantaneously ensure accurate participant identification and qualification for clinical research. Celerion is…
Foster Analytical Services Speed Time to Market for Drug Delivery Formulations
Foster Delivery Science, a business unit for Foster Corporation, recently announced it has added comprehensive in-house laboratory services to expedite the screening of early stage…
Merck KGaA Signs $550 Million Pact With Threshold Pharmaceuticals
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, recently announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to…
Novozymes Wins Innovation Award for Ground-Breaking Half-Life Extension Platform
Novozymes Biopharma, part of Novozymes A/S, recently announced it has received the 2012 Drug Delivery Partnerships (DDP) Technology Innovation award for the company's half-life extension…
OctoPlus Enters Development & Manufacturing Agreement With Ferring Pharmaceuticals
OctoPlus N.V. recently announced a formulation development and manufacturing contract has been signed with Ferring Pharmaceuticals A/S, a leading innovative pharmaceutical company. The undisclosed contract…
